Type 2 diabetes medications

Showing 48 of 52 medications in type 2 diabetes medications (page 1 of 2). Jump to clinical reference & sources below

Filter by condition:
Showing 48 of 52 medications (Page 1 of 2)

Drug Classes & How They Work

  • Oral and non-insulin injectable therapies for type 2 diabetes are grouped into distinct pharmacological classes with complementary mechanisms of action, allowing clinicians to prescribe monotherapy or synergistic combination regimens tailored to baseline renal function, hypoglycemia risk, and weight goals (1.1) (2.1) (4.1).
Pharmacological Class Representative Active Ingredients Primary Mechanism of Action Cardiorenal & Clinical Considerations
Biguanides Metformin hydrochloride (IR and ER) Decreases hepatic gluconeogenesis via AMPK activation; improves peripheral insulin sensitivity Foundational oral therapy; weight-neutral; requires eGFR monitoring and dose adjustment below 45 mL/min/1.73m² (1.1) (2.1)
SGLT2 inhibitors Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin Inhibits renal proximal tubule sodium-glucose cotransporter-2, increasing urinary glucose excretion Demonstrated reduction in heart failure hospitalization and CKD progression; low intrinsic hypoglycemia risk (1.1) (3.1)
GLP-1 & dual GIP/GLP-1 receptor agonists Semaglutide, tirzepatide, liraglutide, dulaglutide Glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central satiety High glycemic and weight-reduction efficacy; ASCVD risk reduction with select agents (1.1) (2.1)
DPP-4 inhibitors Sitagliptin, linagliptin, saxagliptin, alogliptin Inhibits dipeptidyl peptidase-4 enzyme, prolonging endogenous GLP-1 and GIP incretin activity Weight-neutral oral once-daily tablets; minimal hypoglycemia when used without insulin or sulfonylureas (2.1) (4.1)
Sulfonylureas & meglitinides Glimepiride, gliclazide, glipizide, repaglinide Binds pancreatic beta-cell SUR1/Kir6.2 ATP-sensitive potassium channels to stimulate insulin release Effective A1c lowering; carries risk of hypoglycemia and modest weight gain (1.1) (2.1)
Thiazolidinediones (TZDs) Pioglitazone Activates nuclear PPAR-gamma receptors to enhance adipose and muscle insulin sensitivity Durable glycemic control; contraindicated in NYHA Class III/IV heart failure due to fluid retention (2.1) (4.1)

Type 2 diabetes medications: Clinical Overview & Scope

Dosage Forms, Release Profiles & Devices

  • Oral antihyperglycemic medications are manufactured in immediate-release (IR), extended-release (ER/XR), and dual-ingredient fixed-dose combination tablets (2.1) (4.1).
  • Extended-release matrices, such as metformin ER or glipizide XL, release the active drug gradually across the gastrointestinal tract to permit once-daily administration and improve gastrointestinal tolerability; these tablets must be swallowed whole and never crushed, split, or chewed (2.1).
  • Fixed-dose combination tablets (such as sitagliptin/metformin, empagliflozin/metformin, or dapagliflozin/metformin) pair two distinct milligram ratios in a single tablet (for example, 50 mg/500 mg vs. 50 mg/1000 mg), requiring careful verification of both strengths on the prescription label prior to dispensing (2.1) (4.1).

Key Safety, Storage & Monitoring Points

  • Safety monitoring across type 2 diabetes therapies depends on the specific drug class prescribed (1.1) (2.1).
  • Metformin carries a boxed warning for metformin-associated lactic acidosis (MALA); renal function (eGFR) must be assessed at least annually and metformin should be temporarily held prior to iodinated contrast imaging in patients with reduced kidney function (2.1) (4.1).
  • SGLT2 inhibitors increase the risk of genital mycotic infections, volume depletion, and euglycemic diabetic ketoacidosis (DKA), requiring patients to pause therapy 3 to 4 days prior to scheduled surgery (1.1) (2.1).
  • DPP-4 inhibitors and GLP-1 receptor agonists require clinical vigilance for acute pancreatitis (persistent severe abdominal pain radiating to the back), and DPP-4 inhibitors must not be co-administered with GLP-1 receptor agonists due to overlapping incretin pathways (1.1) (3.1).

Ordering & Prescription Checklist for U.S. Patients

  • Match your prescription details: Confirm the active ingredient name, exact milligram or microgram strength, release profile, and package quantity on your U.S. prescription (2.1) (4.1).
  • Licensed pharmacist review: Every order undergoes a dosing, strength, and drug-interaction check in under 1 business day, followed by a mandatory pharmacist consultation before dispatch (3.1).
  • Transparent USD pricing and shipping: Room-temperature medications ship for $14.99 USD flat rate and cold-chain medications ship in $29.99 USD insulated coolers via tracked Canada Post and USPS delivery.
  • Need help matching a product or transferring an Rx? Call 1-888-868-1920 (Monday - Friday: 9:00AM - 6:00PM; Saturday - Sunday: Closed) or review our step-by-step ordering guide and prescription requirements.

Frequently Asked Questions

Why do fixed-dose diabetes combination tablets list two separate milligram numbers?

Combination tablets such as Janumet (sitagliptin/metformin) or Synjardy (empagliflozin/metformin) contain two active ingredients in fixed ratios, such as 5 mg/500 mg, 5 mg/1000 mg, or 12.5 mg/1000 mg (2.1) (4.1). Both numbers must match your prescription exactly, as immediate-release combinations are typically dosed twice daily with meals while extended-release versions are dosed once daily.

Can SGLT2 inhibitors and DPP-4 inhibitors be taken together?

Yes, when prescribed by a clinician. Because SGLT2 inhibitors act in the kidney to excrete glucose and DPP-4 inhibitors act via gut incretin hormones, their mechanisms are complementary and fixed-dose combinations such as Glyxambi (empagliflozin/linagliptin) exist for patients requiring dual therapy (1.1) (2.1).

Does switching from immediate-release to extended-release metformin require a new prescription?

Yes. Immediate-release and extended-release tablets have different pharmacokinetic release profiles and dosing schedules, so any change between release formulations requires prescriber authorization (2.1) (4.1).

References & Official Clinical Sources

Pharmacological classifications, mechanism comparisons, dosing-form distinctions, and clinical safety notes for type 2 diabetes medications are compiled from official regulatory prescribing monographs and medical practice guidelines:

Need help finding your medication? Call 1-888-868-1920.

Call 1-888-868-1920Help